Innovative Bispecific Nanobody Targeting MSLN and TNFRSF9 for Advanced Colon Cancer Therapy

VHH-P203 is a novel, fully humanized nanobody-based bispecific antibody construct currently in the Biological Testing stage. It is designed to target both mesothelin (MSLN) and tumor necrosis factor receptor superfamily member 9 (TNFRSF9), which are critical proteins involved in the progression and immune evasion of colon cancer. By leveraging high specificity to MSLN and TNFRSF9, VHH-P203 offers a promising new direction for the treatment of colon cancer, potentially overcoming conventional therapeutic limitations by engaging cancer cells and modulating the tumor microenvironment. This program exploits the unique characteristics of nanobodies to create a next-generation treatment candidate for a significant oncological challenge.

Licensing Opportunity

VHH-P203 is available for out-licensing and collaborative development opportunities. We welcome inquiries from pharmaceutical partners seeking innovative immuno-oncology assets targeting MSLN and TNFRSF9 for colon cancer.

Development Phase

Modality

VHH-P203 utilizes a sophisticated bispecific antibody modality by fusing an anti-human mesothelin single-domain (nanobody) component to the N-terminus of an IgG1 kappa Fc domain, and further appending an anti-human TNFRSF9 single-chain variable fragment at the Fc’s C-terminus, connected via a flexible (G4S)3 peptide linker. Structurally, nanobodies offer a single-domain format with small molecular size and increased tissue penetration, providing enhanced access to tumor antigens within dense solid tumor environments like those found in colon cancer. The Fc fusion further improves pharmacokinetics and therapeutic stability. Electrostatic modifications and additional disulfide bonds promote molecular integrity and expression efficiency, facilitating scalable manufacturing. Collectively, these features are designed to maximize efficacy, stability, and manufacturability in the clinical development of next-generation colon cancer therapies.

Target

MSLN and TNFRSF9 are critical molecular targets in oncology. MSLN is a cell surface glycoprotein overexpressed in various solid tumors, including colon cancer, where it contributes to tumor cell adhesion, invasion, and metastatic potential, while showing limited expression in normal tissues. TNFRSF9, a member of the tumor necrosis factor receptor superfamily, is predominantly expressed on activated T cells and other immune cells within the tumor microenvironment. Activation of TNFRSF9 enhances T cell proliferation and survival, promoting robust anti-tumor immune responses. As targets, MSLN and TNFRSF9 jointly address both the tumor and the immunological milieu, offering dual mechanisms to restrict tumor growth and empower cytotoxic immune activity. VHH-P203’s dual targeting of MSLN and TNFRSF9 positions it as a strategically valuable asset in immune-oncology pipelines, potentially differentiating this approach in the competitive landscape for advanced colon cancer treatment.

Mechanism of Action

VHH-P203 exerts its anti-tumor effects by binding simultaneously to MSLN on tumor cells and TNFRSF9 on immune effector cells. Through high affinity recognition of MSLN, it selectively localizes to malignant cells in colon cancer tissue. The anti-TNFRSF9 arm engages and activates T cells and other immune subsets, facilitating signal transduction pathways such as co-stimulatory signaling through TNFRSF9 (also known as CD137 or 4-1BB). This synergistic mechanism harnesses targeted cytotoxicity against MSLN-expressing cells while augmenting immune-mediated tumor eradication. The nanobody-based, bispecific architecture opens doors to broader applications, including derivatization as antibody-drug conjugates (ADCs) or multi-specific platforms. VHH-P203 thus represents both an advanced immunotherapeutic strategy and a modular platform for future oncology innovations.

Colon Cancer

Colon cancer remains one of the most prevalent malignant tumors worldwide and a leading cause of cancer-related mortality. The disease arises from the epithelial lining of the large intestine, with incidence influenced by genetic, lifestyle, and environmental factors. Screening allows for early detection, yet many patients are diagnosed at advanced stages. Standard treatments include surgical resection for localized disease, as well as systemic chemotherapy, targeted therapy, and immunotherapy for metastatic cases. However, resistance to existing therapies and recurrence rates pose significant clinical challenges. The efficacy of current options is often limited by tumor heterogeneity, immune suppression within the tumor microenvironment, and inadequate specificity of targeted agents. There is a substantial unmet need for novel therapies that can engage both tumor cells and the immune system more effectively. VHH-P203 offers potential as a targeted immunotherapy for colon cancer, combining tumor-specific recognition with immune activation, paving the way for improved outcomes and new treatment paradigms.